NEW YORK (GenomeWeb News) – Atossa Genetics has increased to 1.3 million the number of shares it plans to offer in its initial public offering, the firm said in a document filed with the US Securities and Exchange Commission on Friday.
The Seattle-based firm had previously targeted an offering of 1.2 million shares of its common stock. It also said last week that it needs to raise at least $6.25 million in gross proceeds from the offering in order to get listed on the Nasdaq Capital Market under ticker symbol "ATOS". It previously had said it needed to raise a minimum of $6 million.
The company continues to expect the share price on its IPO to be between $4 and $6. Dawson James Securities is listed as the underwriter on the offering.
Atossa announced earlier this month a marketing deal for its Mammary Aspirate Specimen Cytology Test System, or MASCT, and the acquisition of the assets of intraductal diagnostic and therapeutic company Acueity Healthcare. Last month, it disclosed a deal to provide access to its tests to providers and patients in managed healthcare plan MultiPlan's networks.